Functional genomics of fibroblasts

Current Opinion in Rheumatology

Volumn 16, Issue 3, 2004, Pages 238-245

  Neumann, Elena ^a   Gay, Renate E ^b   Gay, Steffen ^b   Müller Ladner, Ulf ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Genomics; Matrix destruction; Rheumatoid arthritis; Signaling; Synovial fibroblasts

Indexed keywords

CELL ACTIVATION; CELL PROLIFERATION; CHEMICAL INTERACTION; FIBROBLAST; GENE OVEREXPRESSION; GENOMICS; HUMAN; MOLECULAR DYNAMICS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

APOPTOSIS; ARTHRITIS, RHEUMATOID; CELL ADHESION MOLECULES; CELL DIVISION; FIBROBLASTS; GENOMICS; HUMANS; INFLAMMATION; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 1942435936     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200405000-00012     Document Type: Review

References (61)

1. Sinz A, Bantscheff M, Mikkat S, et al.: Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis. Electrophoresis 2002, 23:3445-3456.
2. Yousef GM, Kopolovic AD, Elliott MB, et al.: Genomic overview of serine proteases. Biochem Biophys Res Commun 2003, 305:28-36.
3. Cuenca J, Cuchacovich M, Perez C, et al.: The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatology 2003, 42:308-313.
4. Grall F, Gu X, Tan L, et al.: Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1. Arthritis Rheum 2003, 48:1249-1260.
5. Andreakos E, Smith C, Kiriakidis S, et al.: Heterogeneous requirement of IkappaB kinase 2 for inflammatory cytokine and matrix metalloproteinase production in rheumatoid arthritis: implications for therapy. Arthritis Rheum 2003, 48:1901-1912.
6. Kishore N, Sommers C, Mathialagan S, et al.: A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in IL-1beta stimulated synovial fibroblasts. J Biol Chem 2003, 278:32861-32871.
7. Elliott SF, Coon CI, Hays E, et al.: Bcl-3 is an interleukin-1-responsive gene in chondrocytes and synovial fibroblasts that activates transcription of the matrix metalloproteinase 1 gene. Arthritis Rheum 2002, 46:3230-3239.
8. Yamasaki S, Nakashima T, Kawakami A, et al.: Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor gamma-mediated signalling pathway. Clin Exp Immunol 2002, 129:379-384.
9. Neumann E, Judex M, Kullmann F, et al.: Inhibition of cartilage destruction by double gene transfer of IL-1 Ra and IL-10 involves the activin pathway. Gene Ther 2002, 9:1508-1519.
10. Shimizu M, Yasuda T, Nakagawa T, et al.: Hyaluronan inhibits matrix metalloproteinase-1 production by rheumatoid synovial fibroblasts stimulated by proinflammatory cytokines. J Rheumatol 2003, 30:1164-1172.
11. Perlman H, Bradley K, Liu H, et al.: IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol 2003, 170:838-845.
12. Nakahara H, Song J, Sugimoto M, et al.: Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48:1521-1529.
13. Min SY, Kim WU, Cho ML, et al.: Prostaglandin E2 suppresses nuclear factor-kappaB mediated interleukin 15 production in rheumatoid synoviocytes. J Rheumatol 2002, 29:1366-1376.
14. Kawashima M, Miossec P: Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis Rheum 2003, 48:631-637. This is an analysis of the differential response of RA synovium cell subsets to IL-18, the effects of IL-18 on Th1 cytokine production, and the regulation of IL-18 by IL-18 binding protein, indicating the role of IL-18 in RA inflammation and joint destruction via T cells and macrophages, but not RASF.
15. Möller B, Paulukat J, Nold M, et al.: Interferon-gamma induces expression of interleukin-18 binding protein in fibroblast-like synoviocytes. Rheumatology 2003, 42:442-445. Detailed investigation about the expression of the endogenous antagonist of IL-18 bioactivity (IL-18 binding protein isoform a) in RASF, showing a negative feedback loop in INF-γ-activated RASF via IL-18 binding protein a, which may limit IL-18 biologic activity in arthritis.
16. Morel JC, Park CC, Zhu K, et al.: Signal transduction pathways involved in rheumatoid arthritis synovial fibroblast interleukin-18-induced vascular cell adhesion molecule-1 expression. J Biol Chem 2002, 277:34679-34691.
17. Schuler MK, Aicher WK: Interleukin-18 is regulated by G protein pathways and protein kinase signals in human fibroblasts. Rheumatol Int 2003.
18. Hirano F, Kobayashi A, Hirano Y, et al.: Thrombin-induced expression of RANTES mRNA through protease activated receptor-1 in human synovial fibroblasts. Ann Rheum Dis 2002, 61:834-837.
19. Hanyuda M, Kasama T, Isozaki T, et al.: Activated leucocytes express and secrete macrophage inflammatory protein-1 alpha upon interaction with synovial fibroblasts of rheumatoid arthritis via a beta2-integrin/ICAM-1 mechanism. Rheumatology 2003, 42:1390-1397.
20. Ruth JH, Shahrara S, Park CC, et al.: Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis. Lab Invest 2003, 83:579-588.
21. Friese MA, Manuelian T, Junnikkala S, et al.: Release of endogenous antiinflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis. Clin Exp Immunol 2003, 132:485-495. This study shows novel, protective antiinflammatory effects of two important complement regulators factor H-link protein-1 and factor H in RA. Both regulators were expressed by RASF and are inducible by interferon-γ and dexamethasone, but not by TNF-α.
22. Liote F, Champy R, Moenner M, et al.: Elevated angiogenin levels in synovial fluid from patients with inflammatory arthritis and secretion of angiogenin by cultured synovial fibroblasts. Clin Exp Immunol 2003, 132:163-168.
23. Gravallese EM, Pettit AR, Lee R, et al.: Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003, 62:100-107. This study examines the angiogenic growth factor angiopoietin-1 in the synovium of patients with RA showing angiopoietin-1 mRNA and protein expression, and an upregulation in RASF by TNF-α. Angiopoietin-1 may therefore contribute to angiogenesis in RA.
24. Woods JM, Mogollon A, Amin MA, et al.: The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp Mol Pathol 2003, 74:282-290.
25. Neidhart M, Seemayer CA, Hummel KM, et al.: Functional characterization of adherent synovial fluid cells in rheumatoid arthritis: destructive potential in vitro and in vivo. Arthritis Rheum 2003, 48:1873-1880. This paper characterizes the morphologic and immunologic features of RA adherent synovial fluid cells and explores their potential function on cartilage destruction. Similar to tissue-derived RASF, RA synovial fluid adherent cells are able to mediate cartilage destruction independent of the hyperplastic synovial tissue.
26. Han MK, Kim JS, Park BH, et al.: NF-kappaB-dependent lymphocyte hyperadhesiveness to synovial fibroblasts by hypoxia and reoxygenation: potential role in rheumatoid arthritis. J Leukoc Biol 2003, 73:525-529. This is an investigation of the effect of hypoxia on the expression of ICAM-1 in RASF and the adherence of lymphocytes to SF. Hypoxia strongly activated NFκB in RASF, caused lymphocyte hyperadhesiveness to RASF, and upregulated ICAM-1, indicating that hypoxia may have a role in sequestration of inflammatory cells to synovium mediated by NFκB activation.
27. Hitchon C, Wong K, Ma G, et al.: Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002, 46:2587-2597. SDF-1 and VEGF expression were expressed under hypoxic conditions in RASF but in contrast to VEGF, SDF-1 was not induced by proinflammatory cytokines such as TNF-α and IL-1β. Hypoxia may therefore contribute to the persistence of synovitis by inducing VEGF and SDF-1.
28. Tolboom TC, Pieterman E, van der Laan WH, et al.: Invasive properties of fibroblast-like synoviocytes: correlation with growth characteristics and expression of MMP-1, MMP-3, and MMP-10. Ann Rheum Dis 2002, 61:975-980. This is an analysis of the relations between the expression of MMP-1 through MMP-14, MMP-17, MMP-19, cathepsin K, TIMP-1, and TIMP-2 in RASF, and the in vitro invasiveness of RASF, showing a significant correlation between higher MMP-1, MMP-3, and MMP-10 levels, and increased invasiveness of RASF into a Matrigel matrix.
29. Itoh T, Matsuda H, Tanioka M, et al.: The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002, 169:2643-2647.
30. Yasuda T, Shimizu M, Nakagawa T, et al.: Matrix metalloproteinase production by COOH-terminal heparin-binding fibronectin fragment in rheumatoid synovial cells. Lab Invest 2003, 83:153-162. The study shows the ability of the COOH-terminal heparin-binding fibronectin fragment and CS-1 to stimulate MMP production in association with activation of MAPK pathways in RASF, in part involving binding of integrin α4β1 in the MMP induction by COOH-terminal heparin-binding fibronectin fragment.
31. Wang J, Lu H, Liu X, et al.: Functional analysis of discoidin domain receptor 2 in synovial fibroblasts in rheumatoid arthritis. J Autoimmun 2002, 19:161-168.
32. Beehler BC, Hei YJ, Chen S, et al.: Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. J Rheumatol 2003, 30:355-363.
33. van der Laan WH, Quax PH, Seemayer CA, et al.: Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther 2003, 10:234-242. Overexpression of TIMP-1 and TIMP-3 resulted in a significant reduction of the RASF invasiveness in a transwell system as well as in the severe combined immunodeficiency mouse model for RA. Besides the inhibition of MMPs, a reduction in proliferation rate could have contributed to this effect.
34. Aicher WK, Alexander D, Haas C, et al.: Transcription factor early growth response 1 activity up-regulates expression of tissue inhibitor of metalloproteinases 1 in human synovial fibroblasts. Arthritis Rheum 2003, 48:348-359. This paper describes investigations about the regulatory potential of Egr-1 on TIMP-1, TIMP-2, and TIMP-3 expression in RASF. Egr-1 binding to a recognition sequence in the TIMP-1 promoter was demonstrated. The same DNA sequence is also recognized by the transcription factor Sp-1. In addition, RASF expressing Egr-1 at high levels were found to express increased levels of TIMP-2 and TIMP-3 mRNA.
35. Alexander D, Judex M, Meyringer R, et al.: Transcription factor Egr-1 activates collagen expression in immortalized fibroblasts or fibrosarcoma cells. Biol Chem 2002, 383:1845-1853.
36. Baig S, Patel Y, Coussons P, et al.: Erythropoietin and interleukin-1beta modulate nitrite production in a Swiss 3T3 cell model of rheumatoid synovial fibroblasts. Biochem Soc Trans 2002, 30:883-886.
37. Corraliza I, Moncada S: Increased expression of arginase II in patients with different forms of arthritis. Implications of the regulation of nitric oxide. J Rheumatol 2002, 29:2261-2265.
38. Miljkovic DJ, Cvetkovic I, Stosic-Grujicic S, et al.: Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts. Clin Exp Immunol 2003, 132:239-246.
39. Wang D, Pechar M, Li W, et al.: Inhibition of cathepsin K with lysosomotropic macromolecular inhibitors. Biochemistry (Mosc) 2002, 41:8849-8859.
40. Wibulswas A, Croft D, Pitsillides AA, et al.: Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis Rheum 2002, 46:2059-2064.
41. Seemayer CA, Kuchen S, Kuenzler P, et al.: Cartilage destruction mediated by synovial fibroblasts does not depend on proliferation in rheumatoid arthritis. Am J Pathol 2003, 161:1549-1557. This paper investigates the relationship between invasion and proliferation in RASF. The study demonstrates that invasion of cartilage is mediated by activated RASF accompanied by increased expression of adhesion molecules, matrix-degrading enzymes, but does not depend on cellular proliferation, as demonstrated by using SV40 immortalized RASF in comparison with nontransformed RASF.
42. Watanabe N, Ando K, Yoshida S, et al.: Gene expression profile analysis of rheumatoid synovial fibroblast cultures revealing the overexpression of genes responsible for tumor-like growth of rheumatoid synovium. Biochem Biophys Res Commun 2002, 294:1121-1129.
43. Kim G, Jun JB, Elkon KB: Necessary role of phosphatidylinositol 3-kinase in transforming growth factor beta-mediated activation of Akt in normal and rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2002, 46:1504-1511.
44. Pufe T, Bartscher M, Petersen W, et al.: Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis. Arthritis Rheum 2003, 48:660-667.
45. Lacey D, Sampey A, Mitchell R, et al.: Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor. Arthritis Rheum 2003, 48:103-109. The purpose of this study was to analyze the role of macrophage MIF in the activation of RASF, and the effects of MIF on synovial cell proliferation: MIF directly regulates RA synovial hyperplasia and via involvement in the effects of IL-1β and TNF-α. The effects of MIF on RASF activation are NFκB independent but may depend on extracellular signal-regulated kinase MAP kinase.
46. Leech M, Lacey D, Xue JR, et al.: Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis. Arthritis Rheum 2003, 48:1881-1889.
47. Kurowska M, Rudnicka W, Kontny E, et al.: Fibroblast-like synoviocytes from rheumatoid arthritis patients express functional IL-15 receptor complex: endogenous IL-15 in autocrine fashion enhances cell proliferation and expression of Bcl-x(L) and Bcl-2. J Immunol 2002, 169:1760-1767.
48. Kyburz D, Rethage J, Seibl R, et al.: Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum 2003, 48:642-650. This study investigates the role of bacterial peptidoglycans in RASF activation and the role of TLRs in activation, showing that bacterial peptidoglycans activate RASF to express integrins, MMPs, and proinflammatory cytokines, and this effect is partially induced via TLR-2.
49. Seibl R, Birchler T, Loeliger S, et al.: Expression and regulation of toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003, 162:1221-1227. The purpose of this study was to investigate whether TLR expression is influenced by IL-1β and TNF-α in RASF. TLR-2 expression was increased after IL-1β and TNF-α treatment. NFκB translocation in RASF was triggered by TLR-2-mediated cell stimulation, and TLR-2 was expressed predominantly at sites of attachment and invasion into cartilage and bone.
50. Lories RJ, Derese I, De Bari C, et al.: In vitro growth rate of fibroblast-like synovial cells is reduced by methotrexate treatment. Ann Rheum Dis 2003, 62:568-571.
51. Wunder A, Müller-Ladner U, Stelzer EH, et al.: Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis. J Immunol 2003, 170:4793-4801. The purpose of this study was to investigate the pharmacokinetics of albumin as a drug carrier for MTX, the uptake of albumin by RASF, and the efficacy of MTX and MTX-HSA in arthritic mice. When compared with MTX, significantly higher amounts of albumin accumulate in inflamed paws. The protein is metabolized by human RASF in vitro and in vivo. MTX-HSA was significantly more effective in onset suppression of arthritis in mice than was MTX.
52. Ichikawa K, Liu W, Fleck M, et al.: TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol 2003, 171:1061-1069. The expression and function of the TRAIL receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) by agonistic monoclonal antibodies in RASF was analyzed. Synovial tissues and primary RASF but not osteoarthritis SF selectively expressed cell surface DR5 and were highly susceptible to anti-DR5 antibody-mediated apoptosis, but no expression of DR4 was detectable.
53. Yao Q, Wang S, Gambotto A, et al.: Intra-articular adenoviral-mediated gene transfer of trail induces apoptosis of arthritic rabbit synovium. Gene Ther 2003, 10:1055-1060.
54. Schedel J, Gay RE, Kuenzler P, et al.: FLICE-inhibitory protein expression in synovial fibroblasts and at sites of cartilage and bone erosion in rheumatoid arthritis. Arthritis Rheum 2002, 46:1512-1518.
55. Krause A, Scaletta N, Ji JD, Ivashkiv LB: Rheumatoid arthritis synoviocyte survival is dependent on Stat3. J Immunol 2002, 169:6610-6616.
56. Attur MG, Dave MN, Tsunoyama K, et al.: A system biology approach to bioinformatics and functional genomics in complex human diseases: arthritis. Curr Issues Mol Biol 2002, 4:129-146.
57. Firestein GS, Pisetsky DS: DNA microarrays: boundless technology or bound by technology? Guidelines for studies using microarray technology. Arthritis Rheum 2002, 46:859-861.
58. Distler O, Gay S, Neumann E, et al.: Minimum information about a microarray experiment. Arthritis Rheum 2003, 48:861-862.
59. Neumann E, Lechner S, Tarner IH, et al.: Evaluation of differentially expressed genes by a combination of cDNA array and RAP-PCR using the AtlasImage 2.0 software. J Autoimmun 2003, 21:161-166.
60. Ball CA, Sherlock G, Parkinson H, et al.: Standards for microarray data. Science 2002, 298:539.
61. Yaspo ML: Taking a functional genomics approach in molecular medicine. Trends Mol Med 2001, 7:494-501.